Vivione Biosciences Inc. (“Vivione”) (TSXV:VBI), through its
wholly owned subsidiary Vivione Biosciences, LLC, is proud to announce
that it has received AOAC (Association of Analytical Communities)
certification for its E. coli O157 and Non O157 STEC diagnostic
tests for the RAPID-B platform. This is Vivione’s first AOAC
certification for its RAPID-B platform, whose technology has the ability
to accurately detect a contamination issue in seven hours or less.
“We are extremely pleased to have been awarded this globally recognized
certification,” said Kevin Kuykendall, CEO of Vivione. “Our technology
is one of the fastest diagnostic tests on the market for E-coli O157
and Non O157 STEC. We believe it represents a new generation of tests
for producers looking for increased sensitivity, accuracy and speed,
with the added benefit of enumerating the bacterial load. Although we’ve
had great interest in our technology over the past two years, now that
we have AOAC certification, producers are able to purchase the RAPID-B
platform to be used for a variety of applications, from incoming
inventory analysis to end product testing.”
The RAPID-B platform offers results in seven hours or less, which is of
great significance when comparing it to other diagnostic testing
platforms that take 24 hours or more to produce results. These benefits
are both economically significant and potentially life-saving. After
almost eight years in development with National Center for Toxicological
Research, Vivione is excited to finally bring these tests to market with
AOAC certification. The AOAC certification is the premiere standard for
the food industry, particularly the beef industry. Food producers look
for the AOAC standard when selecting new platforms and bacterial
contamination tests.
Achieving this milestone, Vivione’s RAPID-B E. coli O157 and Non
O157 STEC tests are positioned to become one of the “go-to” tests used
within the food industry. More importantly, these tests provide
producers with something that they have not had access to prior to
today: a test that can deliver increased sensitivity, while also
significantly reducing the time needed to receive clear test results.
The ability to undertake and report upon a test, beginning with the
receipt and preparation of the sample through to the final analysis, in
seven hours or less instead of the customary 24, stands to allow food
producers to get their products to market faster while reducing
potential recall risk.
About Vivione
Vivione is a TSX Venture Exchange listed biosciences company focused on
the commercialization of its proprietary RAPID-B platform; an integrated
platform of hardware, software and reagents that quickly and accurately
identify, quantify and qualify bacteria and other pathogens in key food
& water safety, clinical, industrial and oil & gas environments. For
more information, visit www.VivioneBiosciences.com.
Cautionary Statements
This news release contains "forward-looking statements" within the
meaning of applicable securities laws. Although Vivione believes that
the expectations reflected in its forward-looking statements are
reasonable, such statements have been based on factors and assumptions
concerning future events that may prove to be inaccurate. These factors
and assumptions are based upon currently available information to
Vivione. Such statements are subject to known and unknown risks,
uncertainties and other factors that could influence actual results or
events and cause actual results or events to differ materially from
those stated, anticipated or implied in the forward-looking statements.
This news release contains forward-looking information relating to the
commercialization and the development of the RAPID-B platform, the
anticipated benefits of receiving AOAC certification and Vivione’s
business and growth strategy. Readers are cautioned to not place undue
reliance on forward-looking statements. The statements in this news
release are made as of the date of this news release and, except as
required by applicable law, Vivione does not undertake any obligation to
publicly update or to revise any of the included forward-looking
statements, whether as a result of new information, future events or
otherwise. Vivione undertakes no obligation to comment on analyses,
expectations or statements made by third-parties in respect of Vivione,
or its financial or operating results or (as applicable), their
securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER
(AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE)
ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Copyright Business Wire 2014